Targeted Therapies: A Paradigm Shift in RCC

Podcast

Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.

Robert J. Motzer, MD

Robert J. Motzer, MD

Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.

Dr. Motzer has led more than 50 clinical trials in patients with kidney cancer and testicular cancer, including national and international multicenter clinical studies. His research has helped identify three targeted antiangiogenesis drugs -- sunitinib (Sutent), temsirolimus (Torisel), and everolimus (Afinitor), as effective first- or second-line treatments for patients with advanced kidney cancer.

Dr. Motzer has been involved in research using anti-angiogenesis agents in advanced RCC. We asked him if we now have a clearer vision of a therapeutic pathway in this challenging setting. “There has been remarkable progress in the treatment of metastatic renal cell carcinoma. This malignancy was considered to be the model for chemo-resistant cancer. Virtually every chemotherapeutic that was tried in this cancer failed to show activity. It became clear that there was a large unmet need in the treatment of RCC, which in a large way presaged the use targeted therapies in this setting,” said Dr. Motzer.

Dr. Motzer explained that over the past 2 decades the primary treatment in advanced renal cell carcinoma has been cytokines, without a good deal of success. However, the treatment paradigm changed with a 2007 trial he led looking at Sunitinib vs Interferon Alpha in Metastatic RCC. “Sunitinib showed improvements in progression-free survival, response, and overall survival. The sunitinib arm also had better quality-of-life measures,” said Dr. Motzer.

Coming up: Dr. Motzer gives his expert perspective on ASCO sessions and abstracts focusing on renal cell carcinoma…also watch for coverage highlights in gastrointestinal cancers, both colorectal and non-colorectal cancers, and special guest Editor Samuel M. Silver, MD, PhD, highlighting sessions on hematological malignancies.

-Interviewed by Ron Piana

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Related Content